UY25687A1 - Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun - Google Patents

Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun

Info

Publication number
UY25687A1
UY25687A1 UY25687A UY25687A UY25687A1 UY 25687 A1 UY25687 A1 UY 25687A1 UY 25687 A UY25687 A UY 25687A UY 25687 A UY25687 A UY 25687A UY 25687 A1 UY25687 A1 UY 25687A1
Authority
UY
Uruguay
Prior art keywords
jun
treatment
jnk
mutated
substance
Prior art date
Application number
UY25687A
Other languages
English (en)
Inventor
Maria Sibilia
Erwin F Wagner
Axel Behrens
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY25687A1 publication Critical patent/UY25687A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método para identificar sustancias para el tratamiento de trastornos asociados con c-Jun, caracterizado porque se ensayan las sustancias en cuanto a su capacidad para inhibir la fosforilación N-terminal de c-Jun; en especial este método ensaya la capacidad de una sustancia para inhibir la interacción física de una quinasa N-terminal de c-Jun con un sustrato c-Jun; y más en particular se incuban con la sustancia de prueba el dominio de fijación para JNK (particularmente JNK3) en c-Jun (como fasL) y el dominio de fijación para c-Jun en una JNK, o proteínas que contienen dichos dominios, estando uno de ellos fusionado a un producto de gen informador (como una proteína con fluorescencia verde), y estando el otro inmovilizado sobre un soporte, y se mide el efecto de la sustancia sobre la interacción física de las dos proteínas midiendo la actividad del producto informador. Ejemplos de trastornos mediados por c-Jun y donde el método es de utilidad para el tratamiento de trastornos neurodegenerativos o neuronales como la apoptosis neuronal, de apoplejía, de una trasformación oncogénica como cáncer, o para el tratamiento de osteosarcoma. También se incluye un animal transgénico, caracterizado porque es homozigótico para un alelo mutado de c-Jun que tiene mutados los sitios de fosfoaceptor de JNK, en particular si tiene mutados ala serina 63 como la serina 73 a alanina.
UY25687A 1998-08-31 1999-08-31 Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun UY25687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98116415A EP0984070A1 (en) 1998-08-31 1998-08-31 Method for identifying substances for the treatment of disorders associated with c-Jun-mediated apoptosis

Publications (1)

Publication Number Publication Date
UY25687A1 true UY25687A1 (es) 2000-03-31

Family

ID=8232547

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25687A UY25687A1 (es) 1998-08-31 1999-08-31 Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun

Country Status (5)

Country Link
EP (1) EP0984070A1 (es)
AU (1) AU5855899A (es)
CO (1) CO5090889A1 (es)
UY (1) UY25687A1 (es)
WO (1) WO2000012754A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10036501B4 (de) * 2000-07-25 2004-08-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur Messung der JNK/SAPKs-Aktivität mittels der Bestimmung der Phosphorylierung von Transkriptionsfaktoren
US7247767B2 (en) 2004-01-21 2007-07-24 Boehringer Ingelheim International Gmbh Mouse model for psoriasis and psoriatic arthritis
US20060148996A1 (en) 2004-12-30 2006-07-06 Coggio William D Low refractive index fluoropolymer compositions having improved coating and durability properties
US9028123B2 (en) 2010-04-16 2015-05-12 Flex Lighting Ii, Llc Display illumination device with a film-based lightguide having stacked incident surfaces
JP2013525955A (ja) 2010-04-16 2013-06-20 フレックス ライティング ２，エルエルシー フィルムベースのライトガイドを備える照明デバイス
WO2011130720A2 (en) 2010-04-16 2011-10-20 Flex Lighting Ii, Llc Sign comprising a film-based lightguide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916806D0 (en) * 1989-07-22 1989-09-06 Univ Wales Medicine Modified proteins
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase

Also Published As

Publication number Publication date
CO5090889A1 (es) 2001-10-30
WO2000012754A8 (en) 2000-08-10
AU5855899A (en) 2000-03-21
WO2000012754A1 (en) 2000-03-09
EP0984070A1 (en) 2000-03-08

Similar Documents

Publication Publication Date Title
Liebl et al. Cell fate regulation upon DNA damage: p53 serine 46 kinases pave the cell death road
D'adda Di Fagagna Living on a break: cellular senescence as a DNA-damage response
Shaw et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling
Birukova et al. Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho‐dependent mechanisms
Bulavin et al. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a
Qiao et al. APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity
Banyasz et al. Transformation of adult rat cardiac myocytes in primary culture
Ookata et al. MAP4 is the in vivo substrate for CDC2 kinase in HeLa cells: identification of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4
Ain et al. Cell cycle-dependent and-independent telomere shortening accompanies murine brain aging
Gonzalez-Suarez et al. Nurturing the genome: A-type lamins preserve genomic stability
Brazina et al. DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase
DE69739898D1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
Baljuls et al. Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase
DE69838090D1 (de) Mehrgefässplatten mit kleiner störstrahlung für fluoreszenzmessungen von biologischen und biochemischen proben
Raurell-Vila et al. An HP1 isoform-specific feedback mechanism regulates Suv39h1 activity under stress conditions
Duesbery et al. Anthrax lethal factor causes proteolytic inactivation of mitogen‐activated protein kinase kinase
Yun et al. Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage
DE69736351D1 (de) Methoden und mittel zur hemmung der cdk4-aktivität
Kumar et al. Activation of p53-dependent/-independent pathways of apoptotic cell death by chelerythrine in a murine T cell lymphoma
UY25687A1 (es) Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun
Cheng et al. Wuho is a new member in maintaining genome stability through its interaction with flap endonuclease 1
Céline De Nadai et al. Evidence for MAP kinase activation during mitotic division
Kostenko et al. Serine residue 115 of MAPK-activated protein kinase MK5 is crucial for its PKA-regulated nuclear export and biological function
Salomon‐Kent et al. New Face for Chromatin‐Related Mesenchymal Modulator: n‐CHD9 Localizes to Nucleoli and Interacts With Ribosomal Genes
Simonatto et al. DNA damage and cellular differentiation: more questions than responses

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110726